MedTrace Logo

Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data

NCT06346821 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 181

Last updated 2024-07-03

No results posted yet for this study

Summary

The goal of this observational study is to learn about the effectiveness of Optune® (Tumor Treating Fields) in newly diagnosed glioblastoma (GBM) in China. The main question it aims to answer are:

* The efficacy of Optune® as an concomitant/adjuvant to radiation therapy (RT) and temozolomide (TMZ) alone in the treatment of newly diagnosed GBM patients.
* The effectiveness of Optune® given concomitantly with RT and TMZ in newly diagnosed GBM patients, compared to RT and TMZ alone.

Participants will:

* Receive or not receive TTFields.
* Concomitantly or adjuvantly receive TTFields.

Conditions

Interventions

DEVICE

Optune® (Tumor Treating Fields)

TTFields at 200 kHz to the brain using the Optune® System

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Lei Liu, PhD, MD · West China Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-22
Primary Completion
2024-04-01
Completion
2024-04-01
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06346821 on ClinicalTrials.gov